Skip to main content

Advertisement

SpringerLink
Log in

Strategies to reduce length of stay and costs associated with decompensated heart failure

  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Heart failure (HF) is a major medical problem in the United States, imposing significant economic burden on the health care system. Despite therapeutic advances, HF-associated morbidity and mortality continue to increase. Compliance with therapeutic guidelines for the management of chronic HF is far from ideal, increasing the likelihood that patients will experience multiple episodes of acute decompensated heart failure (ADHF) during the course of HF disease. Prevention, streamlined inpatient care, effective vasoactive therapy, and initiation of proven long-term therapies, including angiotensin-converting enzyme (ACE) inhibitors and beta-blockers, are all targets for improvement. Because of the chronic nature of heart failure, a successful disease management program for ADHF must also include effective outpatient care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. American Heart Association, American Stroke Association: Heart Disease and Stroke Statistics-2005 Update. http://www.americanheart.org/downloadable/heart/ 1105390918119HDSStats2005Update.pdf. Accessed May 16, 2005.

  2. Ho KKL, Pinsky JL, Kannel WB, Levy D: The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993, 22:6A-13A.

    Article  PubMed  CAS  Google Scholar 

  3. Aghababian RV: Acutely decompensated heart failure: opportunities to improve care and outcomes in the emergency department. Rev Cardiovasc Med 2002, 3(suppl 4):S3-S9.

    PubMed  Google Scholar 

  4. Bonow RO, Smaha LA, Smith SC Jr., et al.: World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 2002, 106:1602–1605.

    Article  PubMed  Google Scholar 

  5. Massie BM, Shah NB: Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 1997, 133:703–712.

    Article  PubMed  CAS  Google Scholar 

  6. Graves EJ, Kozak LJ: National Hospital Discharge Survey: annual summary, 1996. Vital Health Stat 1999, Series 13:1–46.

  7. Peacock WF: Clinical and economic impact of nesiritide. Am J Health Syst Pharm 2003, 60(suppl 4):S21-S26.

    PubMed  Google Scholar 

  8. Jong P, Vowinckel E, Liu PP, et al.: Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med 2002, 162:1689–1694.

    Article  PubMed  Google Scholar 

  9. Peacock WF, Allegra J, Ander D, et al.: Management of acute decompensated heart failure in the emergency department. Congest Heart Fail 2003, 9(5 suppl 1):3–18.

    Google Scholar 

  10. Peacock WF, Emerman CL, Wynne J: Early use of nesiritide in the emergency department is associated with improved outcome: an ADHERE registry analysis. Ann Emerg Med 2004, 44(suppl 4):S78.

    Article  Google Scholar 

  11. Arnold JM, Yusuf S, Young J, et al.: Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003, 107:1284–1290.

    Article  PubMed  CAS  Google Scholar 

  12. Hunt SA, Baker DW, Chin MH, et al.: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001, 38:2101–2113.

    Article  PubMed  CAS  Google Scholar 

  13. Baker DW: Prevention of heart failure. J Card Fail 2002, 8:333–346.

    Article  PubMed  Google Scholar 

  14. Staessen JA, Fagard R, Thijs L, et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) trial investigators. Lancet 1997, 350:757–764.

    Article  PubMed  CAS  Google Scholar 

  15. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265:3255–3264.

    Article  Google Scholar 

  16. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703–713.

    Google Scholar 

  17. Patten RD, Soman P: Prevention and reversal of LV remodeling with neurohormonal inhibitors. Curr Treat Options Cardiovasc Med 2004, 6:313–325.

    PubMed  Google Scholar 

  18. Sigurdsson A, Swedberg K: Prevention of congestive heart failure by ACE inhibition in patients with acute myocardial infarction. J Cardiovasc Risk 1995, 2:406–412.

    Article  PubMed  CAS  Google Scholar 

  19. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685–691.

    Article  Google Scholar 

  20. Kjekshus J, Pedersen TR, Olsson AG, et al.: The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997, 3:249–254.

    Article  PubMed  CAS  Google Scholar 

  21. Luzier AB, Forrest A, Feuerstein SG, et al.: Containment of heart failure hospitalizations and cost by angiotensinconverting enzyme inhibitor dosage optimization. Am J Cardiol 2000, 86:519–523.

    Article  PubMed  CAS  Google Scholar 

  22. Baker DW, Hayes RP, Massie BM, Craig CA: Variations in family physicians’ and cardiologists’ care for patients with heart failure. Am Heart J 1999, 138:826–834.

    Article  PubMed  CAS  Google Scholar 

  23. Cohn JN: Addressing the heart failure management gap. J Card Fail 1999, 5:1–2.

    Article  PubMed  CAS  Google Scholar 

  24. Fonarow GC, Yancy CW, Heywood JT, for the ADHERE Scientific Advisory Committee, Study Group, and Investigators: Adherence to heart failure quality-of-care indicators in US hospitals: analysis of the ADHERE registry. Arch Intern Med 2005, 165:1469–1477.

    Article  PubMed  Google Scholar 

  25. Abookire SA, Karson AS, Fiskio J, Bates DW: Use and monitoring of "statin" lipid-lowering drugs compared with guidelines. Arch Intern Med 2001, 161:53–58.

    Article  PubMed  CAS  Google Scholar 

  26. Rich MW: Heart failure disease management: a critical review. J Card Fail 1999, 5:64–75.

    Article  PubMed  CAS  Google Scholar 

  27. McAlister FA, Lawson FM, Teo KK, Armstrong PW: A systematic review of randomized trials of disease management programs in heart failure. Am J Med 2001, 110:378–384.

    Article  PubMed  CAS  Google Scholar 

  28. Phillips CO, Wright SM, Kern DE, et al.: Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA 2004, 291:1358–1367.

    Article  PubMed  CAS  Google Scholar 

  29. Fonarow GC, Stevenson LW, Walden JA, et al.: Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol 1997, 30:725–732.

    Article  PubMed  CAS  Google Scholar 

  30. Hoskins LM, Clark HM, Schroeder MA, et al.: A clinical pathway for congestive heart failure. Home Healthc Nurse 2001, 19:207–217.

    Article  PubMed  CAS  Google Scholar 

  31. Pearson RR, Horne BD, Maycock CAA, et al.: An institutional heart failure discharge medication program reduces future cardiovascular readmissions and mortality: an analysis of 19,083 heart failure patients. Circulation 2001, 104(suppl):II-838.

    Google Scholar 

  32. Koelling TM, Johnson ML, Cody RJ, Aaronson KD: Discharge education improves clinical outcomes in patients with chronic heart failure. Circulation 2005, 111:179–185.

    Article  PubMed  Google Scholar 

  33. Goldberg LR, Piette JD, Walsh MN, et al., on behalf of the WHARF Investigators: Randomized trial of a daily electronic home monitoring system in patients with advanced heart failure: the Weight Monitoring in Heart Failure (WHARF) trial. Am Heart J 2003, 146:705–712.

    Article  PubMed  Google Scholar 

  34. DeBusk RF, Miller NH, Parker KM, et al.: Care management for low-risk patients with heart failure: a randomized, controlled trial. Ann Intern Med 2004, 141:606–613.

    PubMed  Google Scholar 

  35. Akosah KO, Schaper AM, Havlik P, et al.: Improving care for patients with chronic heart failure in the community: the importance of a disease management program. Chest 2002, 122:906–912.

    Article  PubMed  Google Scholar 

  36. Gorski LA, Johnson K: A disease management program for heart failure: collaboration between a home care agency and a care management organization. Lippincotts Case Manag 2003, 8:265–273.

    Article  PubMed  Google Scholar 

  37. Stewart S, Marley JE, Horowitz JD: Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study. Lancet 1999, 354:1077–1083.

    Article  PubMed  CAS  Google Scholar 

  38. Stewart S, Vandenbroek AJ, Pearson S, Horowitz JD: Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure. Arch Intern Med 1999, 159:257–261.

    Article  PubMed  CAS  Google Scholar 

  39. Stewart S, Horowitz JD: Home-based intervention in congestive heart failure: Long-term implications on readmission and survival. Circulation 2002, 105:2861–2866.

    Article  PubMed  Google Scholar 

  40. Fonarow GC: The treatment targets in acute decompensated heart failure. Rev Cardiovasc Med 2001, 2(suppl 2):S7-S12.

    PubMed  Google Scholar 

  41. Fonarow GC: Pharmacologic therapies for acutely decompensated heart failure. Rev Cardiovasc Med 2002, 3(suppl 4):S18-S27.

    PubMed  Google Scholar 

  42. Bayliss J, Norell M, Canepa-Anson R, et al.: Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987, 57:17–22.

    PubMed  CAS  Google Scholar 

  43. Elkayam U, Akhter MW, Singh H, et al.: Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. Am J Cardiol 2004, 93:237–240.

    Article  PubMed  CAS  Google Scholar 

  44. Southworth MR: Treatment options for acute decompensated heart failure. Am J Health Syst Pharm 2003, 60(suppl 4):S7-S15.

    PubMed  CAS  Google Scholar 

  45. Cuffe MS, Califf RM, Adams KFJ, et al., for the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators: Shortterm intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002, 287:1541–1547. The OPTIME-CHF trial demonstrated that the routine administration of milrinone, an intravenous inotrope, did not improve outcomes for patients admitted with acute decompensated heart failure. Milrinone did not decrease length of stay and did increase the risk of hypotension and atrial fibrillation.

    Article  PubMed  CAS  Google Scholar 

  46. O’Connor CM, Gattis WA, Uretsky BF, et al., for the FIRST Investigators: Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999, 138(1 pt 1):78–86.

    Article  PubMed  CAS  Google Scholar 

  47. Costanzo MR, Saltzberg MT, Gupta V: Early goal-directed therapy in the management of acute heart failure. http://medicalmedia. net/pdf/241.pdf. Medical Media Communications. Accessed July 13, 2005.

  48. Fonarow GC, for the ADHERE™ Scientific Advisory Committee: The Acute Decompensated Heart Failure National Registry (ADHERE™): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003, 4(suppl 7):S21-S30.

    PubMed  Google Scholar 

  49. Butler J, Forman DE, Abraham WT, et al.: Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004, 147:331–338.

    Article  PubMed  Google Scholar 

  50. Gottlieb SS, Abraham W, Butler J, et al.: The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002, 8:136–141.

    Article  PubMed  Google Scholar 

  51. Brunner-La Rocca HP, Kaye DM, Woods RL, et al.: Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001, 37:1221–1227.

    Article  PubMed  CAS  Google Scholar 

  52. Yoshimura M, Yasue H, Morita E, et al.: Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991, 84:1581–1588.

    PubMed  CAS  Google Scholar 

  53. Colucci WS, Elkayam U, Horton DP, et al., for the Nesiritide Study Group: Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000, 343:246–253.

    Article  PubMed  CAS  Google Scholar 

  54. Publication Committee for the VMAC Investigators: Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002, 287:1531–1540. The VMAC trial randomized patients with decompensated heart failure treated with standard therapy to placebo, intravenous nitroglycerin, or nesiritide. The addition of nesiritide to standard therapy improved symptoms and lowered filling pressures more rapidly than nitroglycerin.

    Article  Google Scholar 

  55. Burger AJ, Horton DP, LeJemtel T, et al.: Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT Study. Am Heart J 2002, 144:1102–1108.

    Article  PubMed  CAS  Google Scholar 

  56. Peacock WF IV, Emerman CL, Silver MA, on behalf of the PROACTION Study Group: Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure. Am J Emerg Med 2005, 23:327–331.

    Article  PubMed  Google Scholar 

  57. Chang R, Elatre WA, Heywood JT: Effect of nesiritide on length of hospital stay in patients with decompensated heart failure. J Cardiovasc Pharmacol Ther 2004, 9:173–177.

    Article  PubMed  CAS  Google Scholar 

  58. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K: Shortterm risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005, 293:1900–1905.

    Article  PubMed  CAS  Google Scholar 

  59. Fonarow GC, Adams KF Jr., Abraham WT, et al., for the ADHERE Scientific Advisory Committee, Study Group, and Investigators: Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005, 293:572–580. This important study is an attempt to risk-stratify patients admitted for acute decompensated heart failure. Those patients with a BUN > 43 mg/dL, a systolic blood pressure of < 115 mm Hg, and a serum creatinine > 2.75 mg/dL had an inpatient mortality of nearly 20%, approximately 10-fold higher than patients with normal renal function and blood pressure.

    Article  PubMed  CAS  Google Scholar 

  60. Gottlieb SS, Brater DC, Thomas I, et al.: BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002, 105:1348–1353.

    Article  PubMed  CAS  Google Scholar 

  61. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, et al.: Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation 2004, 109:1680–1685.

    Article  PubMed  CAS  Google Scholar 

  62. Wang DJ, Dowling TC, Meadows D, et al.: Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 2004, 110:1620–1625.

    Article  PubMed  CAS  Google Scholar 

  63. Sackner-Bernstein JD, Skopicki HA, Aaronson KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005, 111:1487–1491.

    Article  PubMed  CAS  Google Scholar 

  64. Emerman CL, Peacock WF, Fonarow GC: Effect of emergency department initiation of vasoactive infusion therapy on heart failure length of stay [abstract 162]. Ann Emerg Med 2002, 40(suppl 4):S46.

    Google Scholar 

  65. Peacock F, Emerman CL, Costanzo MR, et al.: Early initiation of intravenous vasoactive therapy improves heart failure outcomes: an analysis from the ADHERE registry database [abstract 92]. Ann Emerg Med 2003, 42(4 suppl):S26.

    Article  Google Scholar 

  66. DiDomenico RJ, Park HY, Southworth MR, et al.: Guidelines for acute decompensated heart failure treatment. Ann Pharmacother 2004, 38:649–660.

    Article  PubMed  Google Scholar 

  67. Peacock WF, Albert NM: Observation unit management of heart failure. Emerg Med Clin North Am 2001, 19:209–232.

    Article  PubMed  Google Scholar 

  68. Peacock WF: Rapid optimization: strategies for optimal care of decompensated congestive heart-failure patients in the emergency department. Rev Cardiovasc Med 2002, 3(suppl 4):S41-S48.

    PubMed  Google Scholar 

  69. Pantilat SZ, Steimle AE: Palliative care for patients with heart failure. JAMA 2004, 291:2476–2482.

    Article  PubMed  CAS  Google Scholar 

  70. Zambroski CH: Hospice as an alternative model of care for older patients with end-stage heart failure. J Cardiovasc Nurs 2004, 19:76–83.

    PubMed  Google Scholar 

  71. Fox E, Landrum-McNiff K, Zhong Z, et al.: Evaluation of prognostic criteria for determining hospice eligibility in patients with advanced lung, heart, or liver disease. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. JAMA 1999, 282:1638–1645.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Congestive Heart Failure Clinic, Scripps Clinic, 10666 N. Torrey Pines Road, 92037, La Jolla, CA, USA

    J. Thomas Heywood MD

Authors
  1. J. Thomas Heywood MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitchell T. Saltzberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heywood, J.T., Saltzberg, M.T. Strategies to reduce length of stay and costs associated with decompensated heart failure. Curr Heart Fail Rep 2, 140–147 (2005). https://doi.org/10.1007/s11897-005-0022-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-005-0022-2

Keywords

Search

Navigation